ID   KC1D_HUMAN              Reviewed;         415 AA.
AC   P48730; A2I2P2; Q96KZ6; Q9BTN5;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   27-JAN-2003, sequence version 2.
DT   10-MAY-2017, entry version 179.
DE   RecName: Full=Casein kinase I isoform delta;
DE            Short=CKI-delta;
DE            Short=CKId;
DE            EC=2.7.11.1;
DE   AltName: Full=Tau-protein kinase CSNK1D;
DE            EC=2.7.11.26;
GN   Name=CSNK1D; Synonyms=HCKID;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8786104; DOI=10.1006/geno.1996.0091;
RA   Kusuda J., Hidari N., Hidari M., Hashimoto K.;
RT   "Sequence analysis of the cDNA for the human casein kinase I delta
RT   (CSNK1D) gene and its chromosomal localization.";
RL   Genomics 32:140-143(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Hematopoietic stem cell;
RX   PubMed=15070676; DOI=10.1182/blood-2003-08-2768;
RA   Okamura A., Iwata N., Nagata A., Tamekane A., Shimoyama M., Gomyo H.,
RA   Yakushijin K., Urahama N., Hamaguchi M., Fukui C., Chihara K., Ito M.,
RA   Matsui T.;
RT   "Involvement of casein kinase Iepsilon in cytokine-induced
RT   granulocytic differentiation.";
RL   Blood 103:2997-3004(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ENZYME REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=9632646; DOI=10.1074/jbc.273.26.15980;
RA   Rivers A., Gietzen K.F., Vielhaber E., Virshup D.M.;
RT   "Regulation of casein kinase I epsilon and casein kinase I delta by an
RT   in vivo futile phosphorylation cycle.";
RL   J. Biol. Chem. 273:15980-15984(1998).
RN   [7]
RP   FUNCTION AS TP53 KINASE.
RX   PubMed=10606744; DOI=10.1016/S0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [8]
RP   INTERACTION WITH TUBULINS, AND SUBCELLULAR LOCATION.
RX   PubMed=10826492; DOI=10.1078/S0171-9335(04)70027-8;
RA   Behrend L., Stoeter M., Kurth M., Rutter G., Heukeshoven J.,
RA   Deppert W., Knippschild U.;
RT   "Interaction of casein kinase 1 delta (CK1delta) with post-Golgi
RT   structures, microtubules and the spindle apparatus.";
RL   Eur. J. Cell Biol. 79:240-251(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-38 AND THR-176.
RX   PubMed=11161704; DOI=10.1006/excr.2000.5100;
RA   Milne D.M., Looby P., Meek D.W.;
RT   "Catalytic activity of protein kinase CK1 delta (casein kinase 1delta)
RT   is essential for its normal subcellular localization.";
RL   Exp. Cell Res. 263:43-54(2001).
RN   [10]
RP   INTERACTION WITH PER1 AND PER2.
RX   PubMed=11165242; DOI=10.1016/S0014-5793(00)02434-0;
RA   Camacho F., Cilio M., Guo Y., Virshup D.M., Patel K., Khorkova O.,
RA   Styren S., Morse B., Yao Z., Keesler G.A.;
RT   "Human casein kinase Idelta phosphorylation of human circadian clock
RT   proteins period 1 and 2.";
RL   FEBS Lett. 489:159-165(2001).
RN   [11]
RP   FUNCTION AS CONNEXIN-43/GJA1 KINASE, AND INTERACTION WITH
RP   CONNEXIN-43/GJA1.
RX   PubMed=12270943; DOI=10.1074/jbc.M209427200;
RA   Cooper C.D., Lampe P.D.;
RT   "Casein kinase 1 regulates connexin-43 gap junction assembly.";
RL   J. Biol. Chem. 277:44962-44968(2002).
RN   [12]
RP   INTERACTION WITH AKAP9/AKAP450, AND SUBCELLULAR LOCATION.
RX   PubMed=12270714; DOI=10.1016/S0022-2836(02)00857-4;
RA   Sillibourne J.E., Milne D.M., Takahashi M., Ono Y., Meek D.W.;
RT   "Centrosomal anchoring of the protein kinase CK1delta mediated by
RT   attachment to the large, coiled-coil scaffolding protein CG-
RT   NAP/AKAP450.";
RL   J. Mol. Biol. 322:785-797(2002).
RN   [13]
RP   FUNCTION AS MAPT/TAU KINASE, ENZYME REGULATION, AND INTERACTION WITH
RP   MAPT/TAU.
RX   PubMed=14761950; DOI=10.1074/jbc.M314116200;
RA   Li G., Yin H., Kuret J.;
RT   "Casein kinase 1 delta phosphorylates tau and disrupts its binding to
RT   microtubules.";
RL   J. Biol. Chem. 279:15938-15945(2004).
RN   [14]
RP   FUNCTION IN MITOTIC SPINDLE FORMATION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DEVELOPMENTAL STAGE, AND ENZYME REGULATION.
RX   PubMed=16027726; DOI=10.1038/sj.onc.1208941;
RA   Stoeter M., Bamberger A.-M., Aslan B., Kurth M., Speidel D.,
RA   Loening T., Frank H.-G., Kaufmann P., Loehler J., Henne-Bruns D.,
RA   Deppert W., Knippschild U.;
RT   "Inhibition of casein kinase I delta alters mitotic spindle formation
RT   and induces apoptosis in trophoblast cells.";
RL   Oncogene 24:7964-7975(2005).
RN   [15]
RP   CATALYTIC ACTIVITY, AND INTERACTION WITH DBNDD2.
RX   PubMed=16618118; DOI=10.1021/bi052354e;
RA   Yin H., Laguna K.A., Li G., Kuret J.;
RT   "Dysbindin structural homologue CK1BP is an isoform-selective binding
RT   partner of human casein kinase-1.";
RL   Biochemistry 45:5297-5308(2006).
RN   [16]
RP   FUNCTION AS PKD2 KINASE.
RX   PubMed=17962809; DOI=10.1038/sj.emboj.7601891;
RA   von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A.,
RA   Auer A., Van Lint J., Adler G., Seufferlein T.;
RT   "Phosphorylation at Ser244 by CK1 determines nuclear localization and
RT   substrate targeting of PKD2.";
RL   EMBO J. 26:4619-4633(2007).
RN   [17]
RP   FUNCTION AS MAPT/TAU KINASE.
RX   PubMed=17562708; DOI=10.1074/jbc.M703269200;
RA   Hanger D.P., Byers H.L., Wray S., Leung K.-Y., Saxton M.J.,
RA   Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H.;
RT   "Novel phosphorylation sites in tau from Alzheimer brain support a
RT   role for casein kinase 1 in disease pathogenesis.";
RL   J. Biol. Chem. 282:23645-23654(2007).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331 AND SER-384, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   ENZYME REGULATION.
RX   PubMed=19591487; DOI=10.1021/jm9005127;
RA   Peifer C., Abadleh M., Bischof J., Hauser D., Schattel V., Hirner H.,
RA   Knippschild U., Laufer S.;
RT   "3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of
RT   p38alpha mitogen activated protein kinase and casein kinase 1delta.";
RL   J. Med. Chem. 52:7618-7630(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION AS TOP2A KINASE, AND ENZYME REGULATION.
RX   PubMed=19043076; DOI=10.1093/nar/gkn934;
RA   Grozav A.G., Chikamori K., Kozuki T., Grabowski D.R., Bukowski R.M.,
RA   Willard B., Kinter M., Andersen A.H., Ganapathi R., Ganapathi M.K.;
RT   "Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at
RT   serine-1106 and modulates DNA cleavage activity.";
RL   Nucleic Acids Res. 37:382-392(2009).
RN   [24]
RP   FUNCTION AS AIB1/NCOA3 AND ESR1 KINASE, AND INTERACTION WITH
RP   AIB1/NCOA3 AND ESR1.
RX   PubMed=19339517; DOI=10.1093/nar/gkp136;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J.,
RA   Thomas R.S., Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "CK1delta modulates the transcriptional activity of ERalpha via AIB1
RT   in an estrogen-dependent manner and regulates ERalpha-AIB1
RT   interactions.";
RL   Nucleic Acids Res. 37:3110-3123(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   FUNCTION AS DCK KINASE.
RX   PubMed=20637175; DOI=10.1016/j.abb.2010.07.009;
RA   Smal C., Vertommen D., Amsailale R., Arts A., Degand H., Morsomme P.,
RA   Rider M.H., Neste E.V., Bontemps F.;
RT   "Casein kinase 1delta activates human recombinant deoxycytidine kinase
RT   by Ser-74 phosphorylation, but is not involved in the in vivo
RT   regulation of its activity.";
RL   Arch. Biochem. Biophys. 502:44-52(2010).
RN   [27]
RP   FUNCTION AS P53/TP53 KINASE, AND GENE FAMILY.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [28]
RP   FUNCTION AS YAP1 KINASE.
RX   PubMed=20048001; DOI=10.1101/gad.1843810;
RA   Zhao B., Li L., Tumaneng K., Wang C.-Y., Guan K.-L.;
RT   "A coordinated phosphorylation by Lats and CK1 regulates YAP stability
RT   through SCF(beta-TRCP).";
RL   Genes Dev. 24:72-85(2010).
RN   [29]
RP   FUNCTION AS HIF1A KINASE.
RX   PubMed=20699359; DOI=10.1242/jcs.068122;
RA   Kalousi A., Mylonis I., Politou A.S., Chachami G., Paraskeva E.,
RA   Simos G.;
RT   "Casein kinase 1 regulates human hypoxia-inducible factor HIF-1.";
RL   J. Cell Sci. 123:2976-2986(2010).
RN   [30]
RP   FUNCTION IN CIRCADIAN RHYTHMS, AND ENZYME REGULATION.
RX   PubMed=20696890; DOI=10.1073/pnas.1005101107;
RA   Meng Q.-J., Maywood E.S., Bechtold D.A., Lu W.-Q., Li J., Gibbs J.E.,
RA   Dupre S.M., Chesham J.E., Rajamohan F., Knafels J., Sneed B.,
RA   Zawadzke L.E., Ohren J.F., Walton K.M., Wager T.T., Hastings M.H.,
RA   Loudon A.S.I.;
RT   "Entrainment of disrupted circadian behavior through inhibition of
RT   casein kinase 1 (CK1) enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15240-15245(2010).
RN   [31]
RP   FUNCTION IN CIRCADIAN RHYTHMS, AND ENZYME REGULATION.
RX   PubMed=20407760; DOI=10.1007/s00213-010-1860-5;
RA   Sprouse J., Reynolds L., Kleiman R., Tate B., Swanson T.A.,
RA   Pickard G.E.;
RT   "Chronic treatment with a selective inhibitor of casein kinase I
RT   delta/epsilon yields cumulative phase delays in circadian rhythms.";
RL   Psychopharmacology 210:569-576(2010).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   FUNCTION AS EIF6 KINASE, AND ENZYME REGULATION.
RX   PubMed=21084295; DOI=10.1074/jbc.M110.188565;
RA   Biswas A., Mukherjee S., Das S., Shields D., Chow C.W., Maitra U.;
RT   "Opposing action of casein kinase 1 and calcineurin in nucleo-
RT   cytoplasmic shuttling of mammalian translation initiation factor
RT   eIF6.";
RL   J. Biol. Chem. 286:3129-3138(2011).
RN   [35]
RP   FUNCTION AS DVL2 AND DVL3 KINASE, ENZYME REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21422228; DOI=10.1083/jcb.201011111;
RA   Greer Y.E., Rubin J.S.;
RT   "Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a-
RT   dependent neurite outgrowth.";
RL   J. Cell Biol. 192:993-1004(2011).
RN   [36]
RP   ENZYME REGULATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=21258417; DOI=10.1038/onc.2010.627;
RA   Cheong J.K., Nguyen T.H., Wang H., Tan P., Voorhoeve P.M., Lee S.H.,
RA   Virshup D.M.;
RT   "IC261 induces cell cycle arrest and apoptosis of human cancer cells
RT   via CK1delta/epsilon and Wnt/beta-catenin independent inhibition of
RT   mitotic spindle formation.";
RL   Oncogene 30:2558-2569(2011).
RN   [37]
RP   REVIEW ON CIRCADIAN RHYTHMS, AND GENE FAMILY.
RX   PubMed=21145983; DOI=10.1016/j.biocel.2010.12.004;
RA   Cheong J.K., Virshup D.M.;
RT   "Casein kinase 1: Complexity in the family.";
RL   Int. J. Biochem. Cell Biol. 43:465-469(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328; SER-331; SER-382;
RP   SER-384 AND SER-407, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=9761932; DOI=10.1107/S0907444997011724;
RA   Longenecker K.L., Roach P.J., Hurley T.D.;
RT   "Crystallographic studies of casein kinase I delta toward a structural
RT   understanding of auto-inhibition.";
RL   Acta Crystallogr. D 54:473-475(1998).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 1-294 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=22168824; DOI=10.1021/jm201387s;
RA   Long A., Zhao H., Huang X.;
RT   "Structural basis for the interaction between casein kinase 1 delta
RT   and a potent and selective inhibitor.";
RL   J. Med. Chem. 55:956-960(2012).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 1-294 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=23106386; DOI=10.1021/jm301336n;
RA   Long A.M., Zhao H., Huang X.;
RT   "Structural basis for the potent and selective inhibition of casein
RT   kinase 1 epsilon.";
RL   J. Med. Chem. 55:10307-10311(2012).
RN   [43]
RP   VARIANT FASPS2 ALA-44.
RX   PubMed=15800623; DOI=10.1038/nature03453;
RA   Xu Y., Padiath Q.S., Shapiro R.E., Jones C.R., Wu S.C., Saigoh N.,
RA   Saigoh K., Ptacek L.J., Fu Y.H.;
RT   "Functional consequences of a CKIdelta mutation causing familial
RT   advanced sleep phase syndrome.";
RL   Nature 434:640-644(2005).
RN   [44]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-97.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [45]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-97 AND ALA-401.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [46]
RP   VARIANTS FASPS2 ALA-44 AND ARG-46, CHARACTERIZATION OF VARIANTS FASPS2
RP   ALA-44 AND ARG-46, FUNCTION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=23636092; DOI=10.1126/scitranslmed.3005784;
RA   Brennan K.C., Bates E.A., Shapiro R.E., Zyuzin J., Hallows W.C.,
RA   Huang Y., Lee H.Y., Jones C.R., Fu Y.H., Charles A.C., Ptacek L.J.;
RT   "Casein kinase idelta mutations in familial migraine and advanced
RT   phase.";
RL   Sci. Transl. Med. 5:183ra56-183ra56(2013).
CC   -!- FUNCTION: Essential serine/threonine-protein kinase that regulates
CC       diverse cellular growth and survival processes including Wnt
CC       signaling, DNA repair and circadian rhythms. It can phosphorylate
CC       a large number of proteins. Casein kinases are operationally
CC       defined by their preferential utilization of acidic proteins such
CC       as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A,
CC       SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3,
CC       ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central
CC       component of the circadian clock. In balance with PP1, determines
CC       the circadian period length through the regulation of the speed
CC       and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1
CC       and PER2 nuclear transport and degradation. YAP1 phosphorylation
CC       promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated
CC       ubiquitination and subsequent degradation. DNMT1 phosphorylation
CC       reduces its DNA-binding activity. Phosphorylation of ESR1 and
CC       AIB1/NCOA3 stimulates their activity and coactivation.
CC       Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway
CC       that controls neurite outgrowth. EIF6 phosphorylation promotes its
CC       nuclear export. Triggers down-regulation of dopamine receptors in
CC       the forebrain. Activates DCK in vitro by phosphorylation. TOP2A
CC       phosphorylation favors DNA cleavable complex formation. May
CC       regulate the formation of the mitotic spindle apparatus in
CC       extravillous trophoblast. Modulates connexin-43/GJA1 gap junction
CC       assembly by phosphorylation. Probably involved in lymphocyte
CC       physiology. Regulates fast synaptic transmission mediated by
CC       glutamate. {ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:12270943, ECO:0000269|PubMed:14761950,
CC       ECO:0000269|PubMed:16027726, ECO:0000269|PubMed:17562708,
CC       ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:19043076,
CC       ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:20041275,
CC       ECO:0000269|PubMed:20048001, ECO:0000269|PubMed:20407760,
CC       ECO:0000269|PubMed:20637175, ECO:0000269|PubMed:20696890,
CC       ECO:0000269|PubMed:20699359, ECO:0000269|PubMed:21084295,
CC       ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:23636092}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- ENZYME REGULATION: Exhibits substrate-dependent heparin
CC       activation. Drug-mediated inhibition leads to a delay of the
CC       oscillations with the magnitude of this effect dependent upon the
CC       timing of drug administration. Inhibited by phosphorylation.
CC       Repressed by 3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-
CC       one (IC261), N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide
CC       (CKI-7), 4-[4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-
CC       1H-imidazol-2-yl]benzamide (D4476), 3,4-diaryl-isoxazoles and
CC       -imidazoles, and 4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3H-imidazol-
CC       4-yl) pyrimidin-2-ylamine (PF670462, PF670).
CC       {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16027726,
CC       ECO:0000269|PubMed:19043076, ECO:0000269|PubMed:19591487,
CC       ECO:0000269|PubMed:20407760, ECO:0000269|PubMed:20696890,
CC       ECO:0000269|PubMed:21084295, ECO:0000269|PubMed:21258417,
CC       ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:9632646}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=36.5 uM for alpha-casein {ECO:0000269|PubMed:23636092};
CC         KM=635.8 uM for PER2 peptide {ECO:0000269|PubMed:23636092};
CC         KM=180.6 uM for ATP {ECO:0000269|PubMed:23636092};
CC         Note=Maximal velocity nearly identical for the reactions with
CC         alpha-casein and PER2 peptide.;
CC   -!- SUBUNIT: Binds to DNMT1 and MAP1A (By similarity). Monomer.
CC       Component of the circadian core oscillator, which includes the CRY
CC       proteins, CLOCK, or NPAS2, ARTNL/BMAL1 or ARTNL2/BMAL2, CSNK1D
CC       and/or CSNK1E, TIMELESS and the PER proteins. Interacts directly
CC       with PER1 and PER2 which may lead to their degradation. Interacts
CC       with MAPT/TAU, SNAPIN, DBNDD2, AIB1/NCOA3 and ESR1. AKAP9/AKAP450
CC       binding promotes centrosomal subcellular location. Binds to
CC       tubulins in mitotic cells upon DNA damage. {ECO:0000250,
CC       ECO:0000269|PubMed:10826492, ECO:0000269|PubMed:11165242,
CC       ECO:0000269|PubMed:12270714, ECO:0000269|PubMed:12270943,
CC       ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16618118,
CC       ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:22168824,
CC       ECO:0000269|PubMed:23106386}.
CC   -!- INTERACTION:
CC       Q60838:Dvl2 (xeno); NbExp=2; IntAct=EBI-751621, EBI-641940;
CC       Q92997:DVL3; NbExp=4; IntAct=EBI-751621, EBI-739789;
CC       Q96LR2:LURAP1; NbExp=4; IntAct=EBI-751621, EBI-741355;
CC       Q00987:MDM2; NbExp=6; IntAct=EBI-751621, EBI-389668;
CC       Q9C026:TRIM9; NbExp=3; IntAct=EBI-751621, EBI-720828;
CC       Q8IUH5:ZDHHC17; NbExp=3; IntAct=EBI-9087876, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome. Cytoplasm, perinuclear
CC       region. Cell membrane. Cytoplasm, cytoskeleton, spindle. Golgi
CC       apparatus. Note=Localized at mitotic spindle microtubules, and at
CC       the centrosomes and interphase in interphase cells. Recruited to
CC       the spindle apparatus and the centrosomes in response to DNA-
CC       damage. Correct subcellular localization requires kinase activity.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48730-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48730-2; Sequence=VSP_010253;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, including
CC       brain, heart, lung, liver, pancreas, kidney, placenta and skeletal
CC       muscle. However, kinase activity is not uniform, with highest
CC       kinase activity in splenocytes. In blood, highly expressed in
CC       hemopoietic cells and mature granulocytes. Also found in monocytes
CC       and lymphocytes. {ECO:0000269|PubMed:15070676,
CC       ECO:0000269|PubMed:16027726}.
CC   -!- DEVELOPMENTAL STAGE: Highly present in extravillous trophoblast
CC       cells, which are present at the placenta implantation site and
CC       invade the decidua and decidual vessels.
CC       {ECO:0000269|PubMed:16027726}.
CC   -!- PTM: Autophosphorylated on serine and threonine residues; this
CC       autophosphorylation represses activity. Reactivated by
CC       phosphatase-mediated dephosphorylation. May be dephosphorylated by
CC       PP1.
CC   -!- DISEASE: Advanced sleep phase syndrome, familial, 2 (FASPS2)
CC       [MIM:615224]: A disorder characterized by very early sleep onset
CC       and offset. Individuals are 'morning larks' with a 4 hours advance
CC       of the sleep, temperature and melatonin rhythms.
CC       {ECO:0000269|PubMed:15800623, ECO:0000269|PubMed:23636092}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: May be involved in Alzheimer disease by
CC       phosphorylating MAPT/TAU. {ECO:0000305|PubMed:17562708}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. Casein kinase I subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was shown to phosphorylate and activate DCK in vitro but
CC       probably not in vivo. {ECO:0000305|PubMed:20637175}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U29171; AAC50807.1; -; mRNA.
DR   EMBL; U31285; AAC50808.1; -; mRNA.
DR   EMBL; AB091044; BAC10903.1; -; mRNA.
DR   EMBL; AK291758; BAF84447.1; -; mRNA.
DR   EMBL; EF015900; ABM64211.1; -; Genomic_DNA.
DR   EMBL; BC003558; AAH03558.1; -; mRNA.
DR   EMBL; BC015775; AAH15775.1; -; mRNA.
DR   CCDS; CCDS11805.1; -. [P48730-1]
DR   CCDS; CCDS11806.1; -. [P48730-2]
DR   PIR; G01876; G01876.
DR   RefSeq; NP_001884.2; NM_001893.4. [P48730-1]
DR   RefSeq; NP_620693.1; NM_139062.2. [P48730-2]
DR   UniGene; Hs.631725; -.
DR   PDB; 3UYS; X-ray; 2.30 A; A/B/C/D=1-294.
DR   PDB; 3UYT; X-ray; 2.00 A; A/B/C/D=1-294.
DR   PDB; 3UZP; X-ray; 1.94 A; A/B=1-294.
DR   PDB; 4HGT; X-ray; 1.80 A; A/B=1-294.
DR   PDB; 4HNF; X-ray; 2.07 A; A/B=1-294.
DR   PDB; 4KB8; X-ray; 1.95 A; A/B/C/D=3-317.
DR   PDB; 4KBA; X-ray; 1.98 A; A/B/C/D=3-317.
DR   PDB; 4KBC; X-ray; 1.98 A; A/B=1-317.
DR   PDB; 4KBK; X-ray; 2.10 A; A/B/C/D=3-317.
DR   PDB; 4TN6; X-ray; 2.41 A; A/B=1-301.
DR   PDB; 4TW9; X-ray; 2.40 A; A/B=1-295.
DR   PDB; 4TWC; X-ray; 1.70 A; A/B=1-295.
DR   PDB; 5IH4; X-ray; 1.90 A; A=1-294.
DR   PDB; 5IH5; X-ray; 2.25 A; A=1-294.
DR   PDB; 5IH6; X-ray; 2.30 A; A=1-294.
DR   PDBsum; 3UYS; -.
DR   PDBsum; 3UYT; -.
DR   PDBsum; 3UZP; -.
DR   PDBsum; 4HGT; -.
DR   PDBsum; 4HNF; -.
DR   PDBsum; 4KB8; -.
DR   PDBsum; 4KBA; -.
DR   PDBsum; 4KBC; -.
DR   PDBsum; 4KBK; -.
DR   PDBsum; 4TN6; -.
DR   PDBsum; 4TW9; -.
DR   PDBsum; 4TWC; -.
DR   PDBsum; 5IH4; -.
DR   PDBsum; 5IH5; -.
DR   PDBsum; 5IH6; -.
DR   ProteinModelPortal; P48730; -.
DR   SMR; P48730; -.
DR   BioGrid; 107837; 85.
DR   DIP; DIP-39735N; -.
DR   IntAct; P48730; 43.
DR   MINT; MINT-1454355; -.
DR   STRING; 9606.ENSP00000324464; -.
DR   BindingDB; P48730; -.
DR   ChEMBL; CHEMBL2828; -.
DR   GuidetoPHARMACOLOGY; 1997; -.
DR   iPTMnet; P48730; -.
DR   PhosphoSitePlus; P48730; -.
DR   BioMuta; CSNK1D; -.
DR   DMDM; 27923980; -.
DR   EPD; P48730; -.
DR   MaxQB; P48730; -.
DR   PaxDb; P48730; -.
DR   PeptideAtlas; P48730; -.
DR   PRIDE; P48730; -.
DR   TopDownProteomics; P48730-1; -. [P48730-1]
DR   DNASU; 1453; -.
DR   Ensembl; ENST00000314028; ENSP00000324464; ENSG00000141551. [P48730-1]
DR   Ensembl; ENST00000392334; ENSP00000376146; ENSG00000141551. [P48730-2]
DR   GeneID; 1453; -.
DR   KEGG; hsa:1453; -.
DR   UCSC; uc002kei.4; human. [P48730-1]
DR   CTD; 1453; -.
DR   DisGeNET; 1453; -.
DR   GeneCards; CSNK1D; -.
DR   HGNC; HGNC:2452; CSNK1D.
DR   HPA; CAB015410; -.
DR   MalaCards; CSNK1D; -.
DR   MIM; 600864; gene.
DR   MIM; 615224; phenotype.
DR   neXtProt; NX_P48730; -.
DR   OpenTargets; ENSG00000141551; -.
DR   Orphanet; 164736; Familial advanced sleep-phase syndrome.
DR   PharmGKB; PA26952; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   eggNOG; ENOG410XPGP; LUCA.
DR   GeneTree; ENSGT00760000119040; -.
DR   HOGENOM; HOG000182055; -.
DR   HOVERGEN; HBG000176; -.
DR   InParanoid; P48730; -.
DR   KO; K08959; -.
DR   PhylomeDB; P48730; -.
DR   TreeFam; TF300544; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-204005; COPII (Coat Protein 2) Mediated Vesicle Transport.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SABIO-RK; P48730; -.
DR   SignaLink; P48730; -.
DR   SIGNOR; P48730; -.
DR   ChiTaRS; CSNK1D; human.
DR   GeneWiki; CSNK1D; -.
DR   GenomeRNAi; 1453; -.
DR   PRO; PR:P48730; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141551; -.
DR   CleanEx; HS_CSNK1D; -.
DR   ExpressionAtlas; P48730; baseline and differential.
DR   Genevisible; P48730; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:GOC.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IEA:Ensembl.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0097711; P:ciliary basal body docking; TAS:Reactome.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0048208; P:COPII vesicle coating; TAS:Reactome.
DR   GO; GO:0006897; P:endocytosis; IBA:GO_Central.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007030; P:Golgi organization; IMP:SYSCILIA_CCNET.
DR   GO; GO:0007020; P:microtubule nucleation; IMP:SYSCILIA_CCNET.
DR   GO; GO:1905515; P:non-motile cilium assembly; IMP:SYSCILIA_CCNET.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2000052; P:positive regulation of non-canonical Wnt signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:1905426; P:positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation; IC:ParkinsonsUK-UCL.
DR   GO; GO:0071539; P:protein localization to centrosome; IMP:SYSCILIA_CCNET.
DR   GO; GO:0061512; P:protein localization to cilium; IMP:SYSCILIA_CCNET.
DR   GO; GO:0034067; P:protein localization to Golgi apparatus; IMP:SYSCILIA_CCNET.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0006364; P:rRNA processing; TAS:Reactome.
DR   GO; GO:0051225; P:spindle assembly; IDA:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Cell membrane; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; Golgi apparatus; Kinase; Membrane; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN         1    415       Casein kinase I isoform delta.
FT                                /FTId=PRO_0000192833.
FT   DOMAIN        9    277       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      15     23       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      278    364       Centrosomal localization signal (CLS).
FT   REGION      317    342       Autoinhibitory. {ECO:0000250}.
FT   ACT_SITE    128    128       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      38     38       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     328    328       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     331    331       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     370    370       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q06486}.
FT   MOD_RES     375    375       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q9DC28}.
FT   MOD_RES     382    382       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     383    383       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     384    384       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ     400    415       IPGRVASSGLQSVVHR -> NSIPFEHHGK (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010253.
FT   VARIANT      44     44       T -> A (in FASPS2; strongly reduces
FT                                kinase activity; dbSNP:rs104894561).
FT                                {ECO:0000269|PubMed:15800623,
FT                                ECO:0000269|PubMed:23636092}.
FT                                /FTId=VAR_029075.
FT   VARIANT      46     46       H -> R (in FASPS2; strongly reduces
FT                                kinase activity; dbSNP:rs397514693).
FT                                {ECO:0000269|PubMed:23636092}.
FT                                /FTId=VAR_069801.
FT   VARIANT      97     97       S -> C (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_036451.
FT   VARIANT     401    401       P -> A (in dbSNP:rs56124628).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042081.
FT   MUTAGEN      38     38       K->M: Impaired kinase activity and
FT                                abnormal subcellular localization with
FT                                exclusive accumulation to the nucleus.
FT                                {ECO:0000269|PubMed:11161704}.
FT   MUTAGEN     176    176       T->I: Impaired kinase activity and
FT                                abnormal subcellular localization with
FT                                exclusive accumulation to the nucleus.
FT                                {ECO:0000269|PubMed:11161704}.
FT   CONFLICT    330    330       A -> D (in Ref. 1; AAC50807).
FT                                {ECO:0000305}.
FT   STRAND        3      5       {ECO:0000244|PDB:4TWC}.
FT   TURN          6      8       {ECO:0000244|PDB:4TWC}.
FT   STRAND        9     16       {ECO:0000244|PDB:4TWC}.
FT   STRAND       21     28       {ECO:0000244|PDB:4TWC}.
FT   TURN         29     32       {ECO:0000244|PDB:4TWC}.
FT   STRAND       33     41       {ECO:0000244|PDB:4TWC}.
FT   STRAND       44     46       {ECO:0000244|PDB:4TWC}.
FT   HELIX        49     59       {ECO:0000244|PDB:4TWC}.
FT   STRAND       68     74       {ECO:0000244|PDB:4TWC}.
FT   STRAND       77     83       {ECO:0000244|PDB:4TWC}.
FT   HELIX        89     95       {ECO:0000244|PDB:4TWC}.
FT   TURN         96     98       {ECO:0000244|PDB:4TWC}.
FT   HELIX       102    121       {ECO:0000244|PDB:4TWC}.
FT   HELIX       131    133       {ECO:0000244|PDB:4TWC}.
FT   STRAND      134    136       {ECO:0000244|PDB:4TWC}.
FT   HELIX       139    141       {ECO:0000244|PDB:4TWC}.
FT   STRAND      145    147       {ECO:0000244|PDB:4TWC}.
FT   STRAND      154    157       {ECO:0000244|PDB:4TWC}.
FT   TURN        159    161       {ECO:0000244|PDB:4TWC}.
FT   HELIX       177    179       {ECO:0000244|PDB:4TWC}.
FT   HELIX       182    185       {ECO:0000244|PDB:4TWC}.
FT   HELIX       192    208       {ECO:0000244|PDB:4TWC}.
FT   TURN        212    215       {ECO:0000244|PDB:4KB8}.
FT   HELIX       223    234       {ECO:0000244|PDB:4TWC}.
FT   HELIX       237    240       {ECO:0000244|PDB:4TWC}.
FT   TURN        241    243       {ECO:0000244|PDB:4TWC}.
FT   HELIX       247    257       {ECO:0000244|PDB:4TWC}.
FT   HELIX       266    279       {ECO:0000244|PDB:4TWC}.
FT   TURN        289    292       {ECO:0000244|PDB:4TWC}.
SQ   SEQUENCE   415 AA;  47330 MW;  B97F1717A52466D2 CRC64;
     MELRVGNRYR LGRKIGSGSF GDIYLGTDIA AGEEVAIKLE CVKTKHPQLH IESKIYKMMQ
     GGVGIPTIRW CGAEGDYNVM VMELLGPSLE DLFNFCSRKF SLKTVLLLAD QMISRIEYIH
     SKNFIHRDVK PDNFLMGLGK KGNLVYIIDF GLAKKYRDAR THQHIPYREN KNLTGTARYA
     SINTHLGIEQ SRRDDLESLG YVLMYFNLGS LPWQGLKAAT KRQKYERISE KKMSTPIEVL
     CKGYPSEFAT YLNFCRSLRF DDKPDYSYLR QLFRNLFHRQ GFSYDYVFDW NMLKFGASRA
     ADDAERERRD REERLRHSRN PATRGLPSTA SGRLRGTQEV APPTPLTPTS HTANTSPRPV
     SGMERERKVS MRLHRGAPVN ISSSDLTGRQ DTSRMSTSQI PGRVASSGLQ SVVHR
//
